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ABSTRACT 
Cachexia is very common among patients with advanced pancreatic cancer and is a 
marker of poor prognosis. Weight loss in cachexia is due to both adipose and muscle 
compartments, and sarcopenia (severe muscle depletion) is associated with worse outcomes. 
Curcumin has shown a myriad of biological effects, including anti-cancer and anti-
inflammatory. The ability of curcumin to attenuate cachexia and muscle loss has been tested 
in animal models, with conflicting results so far. The hypothesis of this study was that 
patients with advanced pancreatic cancer treated with curcumin for two months have less fat 
and muscle loss as compared to matched controls not treated with this compound. A 
matched 1:2 case-control retrospective study was conducted with 22 patients with pancreatic 
cancer who were treated with curcumin on a previous protocol and 44 untreated controls 
with the same diagnosis matched by age, gender, time from advanced cancer, body mass 
index, and number of prior therapies. Data was collected regarding oncologic treatment, 
medication use, weights, heights, and survival. Body composition was determined by 
computerized tomography analyses at two timepoints separated by 60±20 days. For treated 
patients, the first image was at the beginning of treatment and for controls it was determined 
by the matching time from advanced cancer. The evolution of body composition over time 
was quantitatively analyzed comparing both groups. All patients lost weight both due to fat 
and muscle losses, and patients treated with curcumin presented greater losses both in lean 
adipose body mass. Use of medications, chemotherapy, age, time from advanced cancer, 
baseline albumin, performance status, and number of prior therapies were not independently 
correlated with changes in body composition variables. Patients treated with curcumin had 
borderline shorter survival when compared with untreated patients. Sarcopenic treated 
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patients had significantly shorter survival than non-sarcopenic counterparts, and sarcopenia 
status was not associated with survival among the controls. Treated patients with shorter 
survival showed a tendency to lose more lean and especially fat body mass as compared to 
untreated patients, maybe suggesting an effect of curcumin on shifting weight loss towards 
the end of life by impacting its mechanisms.  
 
 
 
 viii 
 
TABLE OF CONTENTS 
DEDICATION ........................................................................................................................ iii 
ACKNOWLEDGEMENTS .................................................................................................... iv 
ABSTRACT ........................................................................................................................... vi 
LIST OF ILLUSTRATIONS .................................................................................................. xi 
LIST OF TABLES ................................................................................................................. xii 
ABBREVIATIONS .............................................................................................................. xiii 
CHAPTER 1 – Introduction to cancer cachexia ...................................................................... 1 
Statement of importance ...................................................................................................... 1 
Definition ............................................................................................................................. 1 
Epidemiology ....................................................................................................................... 2 
Pathophysiology .................................................................................................................. 2 
Energy balance and appetite regulation ........................................................................... 3 
Pathogenesis of cancer anorexia .................................................................................. 5 
Adipose tissue metabolism in cancer cachexia ................................................................ 7 
Muscle metabolism in cancer cachexia - Sarcopenia ...................................................... 8 
Trophic influence on skeletal muscle in cancer cachexia ................................................ 9 
Inflammation .................................................................................................................. 10 
CHAPTER 2 – Curcumin ...................................................................................................... 12 
Origins and biochemistry ................................................................................................... 12 
 ix 
 
Actions and molecular targets ........................................................................................... 13 
Curcumin and cachexia ...................................................................................................... 14 
CHAPTER 3 – RATIONALE, HYPOTHESIS, AND AIMS ............................................... 15 
Rationale ............................................................................................................................ 15 
Hypothesis ......................................................................................................................... 15 
Specific Aims ..................................................................................................................... 15 
CHAPTER 4 – METHODOLOGY ....................................................................................... 16 
Patient population .............................................................................................................. 16 
Inclusion criteria ............................................................................................................ 16 
Exclusion criteria ........................................................................................................... 17 
Control matching procedure .......................................................................................... 18 
Data collection ................................................................................................................... 19 
Body composition determination by CT image analyses .................................................. 20 
Procedure ....................................................................................................................... 20 
Statistical analyses ............................................................................................................. 22 
CHAPTER 5 – RESULTS ..................................................................................................... 24 
Study sample ...................................................................................................................... 24 
Body weight ....................................................................................................................... 26 
Body composition .............................................................................................................. 27 
Survival analyses ............................................................................................................... 33 
 x 
 
Exploratory pre-baseline data analyses ............................................................................. 38 
Treatment responders exploratory analyses ....................................................................... 39 
CHAPTER 6 – DISCUSSION ........................................................................................... 40 
Curcumin did not seem to reverse nor attenuate body mass losses ................................... 40 
Curcumin and survival ....................................................................................................... 43 
Potential confounders of body composition changes ........................................................ 46 
Exploratory analyses of the best responders ...................................................................... 47 
CHAPTER 7 – CONCLUSIONS AND FINAL CONSIDERATIONS ................................ 49 
BIBLIOGRAPHY.................................................................................................................. 51 
VITA ...................................................................................................................................... 71 
 
 
 
  
 
 xi 
 
LIST OF ILLUSTRATIONS 
 
FIGURE 1 – Schematic representation of the mechanisms of cancer cachexia ....................  3 
FIGURE 2 – CT image body composition determination procedure ..................................  21 
FIGURE 3 – Study population flowchart  ............................................................................ 24 
FIGURE 4 – Percent weight change in the study groups ....................................................  27 
FIGURE 5 – Percent change in body composition variables between baseline and follow up 
 .............................................................................................................................................   31 
FIGURE 6 – Kaplan-Meier plot: survival from baseline of patients in the treatment and 
control groups  ....................................................................................................................... 34 
FIGURE 7 –Kaplan-Meier plots: survival of sarcopenic and non sarcopenic patients .......  34 
FIGURE 8 – Percent change in lean body mass according to survival from baseline ........  36 
FIGURE 9 – Percent change in adipose body mass according to survival from baseline ..  37 
FIGURE 10 – Percent weight changes at three time points ................................................  38 
 
 
 
 
 
 
 
 
 
 
 
 xii 
 
LIST OF TABLES 
 
TABLE 1 – Results of the matching process  .................................................................... 25 
TABLE 2 – Weight and BMI values for patients in both study groups at the 2 time points 
 ............................................................................................................................................ 26 
TABLE 3 –Body composition variables in both groups at baseline and follow up ...........  28 
TABLE 4 – Correlations between body composition variation and confounding variables 
 ............................................................................................................................................ 33 
TABLE 5 – Body composition changes in the responder patients and their controls .......  39 
 
 
 
 
 
 
 
 
 
 xiii 
 
ABBREVIATIONS 
 
AgRP = agouti-related protein 
ALT = alanine aminotransferase 
AST = aspartate aminotransferase 
BC = before Christ 
BMI =body mass index 
CART = cocaine-amphetamine-related transcript 
CHF = congestive heart failure 
CI = confidence interval 
cm = centimeter 
COPD = chronic obstructive pulmonary disease  
CT = computerized tomography 
DEXA = dual X-ray absortiometry 
DICOM = digital imaging and communication in medicine 
dL = deciliters 
FM = fat mass 
GABA = γ-aminobutyric acid 
HU = Hounsfield units 
IFNγ = interferon gamma 
IL1 = interleukin 1 
IL2 = interleukin 2 
IL6 = interleukin 6 
IQR = interquartile range 
 xiv 
 
L3 = third lumbar vertebra 
LBM = lean body mass 
LMF = lipid mobilizing factor 
m = meter 
Malonyl-CoA = malonyl coenzyme A 
MAPK = mitogen-activated protein kinase 
MCH = melanin-concentrating hormone 
MCR4 = melanocortin-4 
mg = milligrams 
mm = millimeters 
mRNA = messenger ribonucleic acid 
NF-κB = nuclear factor κB 
NPY = neuropeptide Y 
PACS = picture archiving and communication system 
PD = progressive disease 
PIF = proteolysis inducing factor 
POMC = pro-opiomelanocortin  
PPARγ = peroxisome proliferator-activated receptor γ 
r = correlation coefficient 
ROS = reactive oxygen species 
SD = standard deviation 
SE = side effect  
SEM = standard error of the mean 
 xv 
 
STAT = signal transducer and activator of transcription 
TNFα = tumor necrosis factor alpha 
TRH = thyrotrophin-releasing hormone 
ULN = upper limit of normality 
ZAG = zinc-α2-glycoprotein 
βHCG = human corionic gonadotropin, fraction beta. 
 
 
 1 
 
CHAPTER 1 – Introduction to cancer cachexia 
 
Statement of importance 
The whole spectrum of abnormalities in the amount of body fat and muscle (body 
composition) has been associated to cancer prevention, treatment outcomes, and survival. 
Increased body weight (overweight and obesity) has been associated with predisposition for 
several types of cancers such as endometrial, breast (in postmenopausal woman), colon, 
kidney, and esophagus (1-3). On the other hand, loss of body mass (both fat and lean 
contents), broadly termed “cancer cachexia” has been associated with worse outcomes such 
as decreased survival in patients with pancreatic cancer, loss of physical strength, and poorer 
response to therapy (4-7) . To date, there is no effective treatment for the loss of body mass 
in cancer cachexia. Finding strategies to fight this condition will allow for better patient care 
as it allows better outcomes of cancer treatment and increased quality of life. 
 
Definition 
The term cachexia comes from the Greek words kakós (bad) and hexis (condition, state) 
(8). In broad terms, cachexia is defined by an involuntary weight loss accompanied by 
various degrees of associated factors such as anorexia, decline in muscular strength, and 
inflammation (9). Recently, a specific definition of cancer cachexia has been suggested and 
states that it is “a multi-factorial syndrome defined by an ongoing loss of skeletal muscle 
mass (with or without loss of fat mass) that cannot be fully reversed by conventional 
nutritional support and leads to progressive functional impairment. The pathophysiology is 
characterized by a negative protein and energy balance driven by a variable combination of 
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reduced food intake and abnormal metabolism.” (10). Clinically, a patient is considered to 
have cancer cachexia in the presence of weight loss greater than 5% in the past 6 months (if 
simple starvation can be excluded) or any weight loss greater than 2% if the patient has a 
BMI lower than 20 kg/m
2
. Additionally, a patient can be diagnosed with cachexia if a weight 
loss greater than 2% is present combined with sarcopenia (defined as an appendicular 
skeletal muscle index lower than 7.26 kg/m
2
 for males and 5.45 kg/m
2
 for females) (10). 
 
Epidemiology 
Overall, half of all patients with cancer lose some weight in the course of their diseases 
(11). However, the prevalence of weight loss in patients with cancer is highly variable, and 
it is significantly more frequent among patients with solid tumors, in which up to 80% have 
weight loss of at least 5% of the premorbid body weight (5). In the last weeks of life, the 
prevalence of weight loss in patients with cancer has been described as 86% (12), and 
around 20% of all cancer deaths are directly related to cachexia (11).  
In patients with pancreatic cancer, a 10% weight loss in comparison with premorbid 
weight is present in approximately 80% of all cases, and at least 25% of these cases 
presented cancer cachexia (6). 
 
Pathophysiology 
Cancer cachexia is multi-factorial and usually understood as having two major groups 
of causal factors. One group encompasses the effect of the tumor and the body’s responses 
to its presence, and is usually referred to as “primary cachexia”. The other group comprises 
a myriad of conditions that can co-occur and affect energy intake (such as nausea, stomatitis, 
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taste abnormalities, cognitive impairment, bowel obstruction, dental problems, for example), 
protein balance (ageing, concomitant corticosteroid use, ascitis/pleural effusion repeat 
drainage, for example), and induce catabolic states (such as infections, heart failure, 
hypothyroidism, for example) (Figure 1) (13). The pathophysiology of primary cachexia will 
be discussed here, and it is best understood by taking into account energy balance, muscle 
and fat metabolism, and the influence of inflammation on catabolism.  
 
 
 
 
FIGURE 1 – Schematic representation of the mechanisms of cancer cachexia. 
 
Energy balance and appetite regulation 
Body weight is maintained relatively constant in healthy individuals when the energy 
balance is kept neutral. In other words, energy expenditure and energy intake are equivalent 
(14). In animal models, it has been proven that this equilibrium is tightly maintained by 
coordinated mechanisms: in times of low energy availability, oxygen consumption is 
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lowered, and when energy supply is abundant, basal metabolism and energy expenditure 
increase (15). Energy (food) intake is controlled by a hypothalamic system which integrates 
several afferent signals from organs such as the gastrointestinal tract, the liver, and adipose 
tissue (16).  
The central hypothalamic integrative system is located adjacent to the third ventricle in 
the arcuate nucleus and is composed of two neuronal populations: the orexigenic pathway 
(which promotes food intake and reduces energy loss) and the anorexigenic pathway (which 
in turn inhibits food intake and promotes energy use) (16). The orexigenic pathway neurons 
express neuropeptide Y (NPY) and the agouti-related protein (AgRP) whereas the 
anorexigenic pathway neurons express pro-opiomelanocortin (POMC) and cocaine-
amphetamine-related transcript (CART) (16). The message integrated in hypothalamus is 
relayed to several effector neuron populations, most importantly: (a) the melanin-
concentrating hormone (MCH) and the orexin/hypocretin neurons, which have downstream 
orexigenic effect, ultimately leading to an increase in food intake (17-22); (b) neurons 
expressing thyrotrophin-releasing hormone (TRH), which ultimately exert an anorexigenic 
effect (23, 24); and (c) neurons secreting γ-aminobutyric acid (GABA), capable of 
modulation of both orexigenic and anorexigenic pathways (25, 26). 
The afferent signals to the hypothalamic integrative center come from several organs 
via different pathways. Ghrelin, for example, is mostly produced in the stomach in response 
to fasting, but also produced in smaller amounts by other organs (27), and exerts an 
orexigenic effect both by activating NPY/AgRP neurons and inhibiting POMC/CART 
neurons in the hypothalamic integrative center (27, 28). One group of specific afferent 
signals “inform” the hypothalamus about the adiposity status of the body. Leptin is an 
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important afferent adiposity signal arising from the adipocytes in response to the amount of 
energy stored (greater energy storage amounts are linked to increased leptin levels), with 
direct excitation of POMC/CART neurons and inhibition of NPY/AgRP neurons, decreasing 
food intake and increasing the metabolic rate (16, 29, 30). Another adipositiy-related signal 
is conveyed by insulin, which is secreted by the pancreas in response to adiposity and also 
has inhibitory action over NPY/AgRP neurons and excitatory action over POMC/CART 
neurons (31, 32).  
The energy signals, another group of afferent signals, are responsible for “informing” 
the hypothalamus about the energy status of the organism. The most important of those 
signals is conveyed by the differential concentration of malonyl coenzyme A (malonyl-CoA) 
in the hypothalamus, which increases in the presence of abundant fatty acids (signaling to 
reduce appetite) and decreases when fatty acid concentration is low (signaling to increase 
appetite) (33). Another energy signal comes from specialized cells sitting mainly in the 
ileum and colon (L cells). Such cells respond to the presence of food and specifically its 
caloric content by proportionately secreting peptide YY which has inhibitory action on 
NPY/AgRP neurons, therefore with an anorexigenic effect (34, 35). 
Pathogenesis of cancer anorexia 
The pathogenesis of cancer anorexia is yet to be completely understood. Nevertheless, 
evidence both from cancer animal models and from clinical studies point to several 
derangements within the complex machinery that regulates energy intake. Several studies 
failed to show a direct involvement of leptin (36, 37) and ghrelin (38, 39) in the genesis of 
cancer anorexia, pointing towards a more central (hypothalamic) issue. There is evidence, 
for example, showing that in the tumor-bearing state, brain neurochemistry can be changed 
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in specific brain areas, including the hypothalamus (40). Another argument favoring the 
hypothesis of a hypothalamic derangement comes from research with NPY. It has been 
shown that in anorexic tumor-bearing rats there is a significant decrease in NPY 
imunorreactive neurons in the hypothalamus, suggesting that this might be part of the 
genesis of anorexia in those animals (41). There is also evidence pointing towards the 
impairment of the anorexigenic pathway in cancer anorexia. It has been shown that in 
anorexic tumor-bearing rats in which POMC/CART neurons were inactivated the food 
seeking behavior is restored (42, 43) and that in melanocortin-4 (MCR4) knock-out mice (in 
which the activation of the POMC/CART pathway is incomplete) tumor growth is not 
accompanied by anorexia as expected (42). It seems that cytokines play a major role in this 
hypothalamic derangement (44). For example, injections of mianserin (an antagonist of the 
IL1 receptor) directly to the hypothalamus of tumor-bearing anorexic rats were able to 
increase food intake (45). Also supporting this, it has been shown in an animal model of 
prostate adenocarcinoma that anorexia is associated with a detectable increase of IL1β 
mRNA (46). 
The mechanisms through which cytokines directly affect the hypothalamic control of 
energy intake have been widely studied, and evidence now shows that cytokines act on the 
melanocortin system mostly through serotonin release in the hypothalamus (47). 
Fenfluramine, a serotonin agonist, has been shown to increase the concentration of serotonin 
in the hypothalamus, inducing anorexia by activating POMC/CART neurons (48). Also, it 
has been shown that in anorexic tumor-bearing rats the levels of hypothalamic serotonin are 
significantly higher than those of normal rats, and when the cancer is removed, the serotonin 
levels return to those of normal rats (49). In the clinical setting, the findings from animal 
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models were confirmed by quantification of tryptophan (serotonin precursor) in the 
cerebrospinal fluid of anorectic patients with cancer. These patients presented significantly 
higher levels of  free tryptophan when compared to healthy volunteers or non-anorectic 
cancer patients (50). In addition, the same group was able to show that when the tumor is 
removed, the tryptophan levels return to premorbid levels (51). 
 
Adipose tissue metabolism in cancer cachexia 
Adipose tissue is the largest energy reservoir in the human body. In healthy individuals, 
adipose tissue stores triacylglicerol when energy balance is positive and releases non-
sterified fatty acids when such balance is negative (52). Loss of adipose tissue is an 
important feature of cancer cachexia. It has been shown by evaluation of cancer patients’ 
body composition by dual X-Ray absortiometry that the loss of adipose tissue precedes that 
of skeletal muscle, and this was confirmed by computerized tomography analyses in a 
different sample (53, 54). The major driver of lipid metabolism abnormalities in cancer 
cachexia is a reduction in lipoprotein lipase activity, reducing the catabolism of triglycerides 
and therefore impeding its accumulation in the adipocytes (55).  This inhibition of 
lipoprotein lipase occurs mainly as a result of direct action of cytokines such as IL2 (56) and 
TNFα (57). The latter is also capable of increase lipolysis from the adipocytes themselves, 
by inhibiting the adipose tissue hormone-sensitive lipase (58). 
Another important player in the changes in adipose tissue of cachectic individuals is the 
so-called Lipid Mobilizing Factor (LMF) which is a protein (zinc-α2-glycoprotein, ZAG) 
identified in an animal model of cancer cachexia and found in the urine of cachectic 
patients. ZAG is an adipokine produced by the adipose tissue which locally regulates fat 
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mass and is overexpressed in several types of cancers (52). In vitro models show that ZAG 
induces lipolysis in cultured adipocytes (52) and studies in animals demonstrated that ZAG-
induced weight loss is specifically due to adipose tissue loss (59). In humans, it has been 
shown that ZAG expression and concentration of mRNA is increased in the adipose tissue of 
cachectic patients (52). 
 
Muscle metabolism in cancer cachexia - Sarcopenia 
As it is for energy, muscle metabolism is also mostly based on the balance between 
protein synthesis and protein degradation (60). In the setting of cancer cachexia, both a 
reduction in protein synthesis (hypoanabolism) and an increase in its degradation 
(hypercatabolism) is observed (60, 61). To date, there is some debate on the importance of 
each alteration (62), but most studies are focused in the hypercatabolism aspect. 
Three major proteolytic systems are usually described: the lysossomal, the calcium 
dependant, and the adenosine triphosphate- dependent ubiquitin-proteasome pathways (63). 
In cancer cachexia, there is evidence of a preponderance of the latter, since in tumor-bearing 
rats with increased proteolysis the inhibition of both lysossomal and calcium-dependant 
pathways did not lead to reduction in proteolysis. Additionally, ubiquitin levels in the 
atrophying muscles increased, therefore, the conclusion was that the ubiquitin-proteasome 
pathway was the driving force behind muscle atrophy in this model (64). 
In patients with cancer, the increased activity of the proteasome is believed to be caused 
by several abnormalities such as increased oxidative stress, cytokines, and presence of the 
tumor-secreted proteolysis inducing factor. Increased oxidative stress has been proven to 
induce proteasome activity (65), and there is evidence that muscle wasting in animal models 
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is not only induced by oxidative stress but also can be prevented by antioxidants (66). It is 
believed that oxidative stress activates the expression of genes in the ubiquitin-proteasome 
pathway through TNFα and NFκB activity (67). 
 Cytokines such as IL1, IL6, IFNγ, and TNFα have been shown to be involved in the 
genesis of muscle atrophy in animal models of cachexia. TNFα administration caused an 
increase in protein degradation with increase in proteasome gene expression and ubiquitin 
levels (68). Innoculation of rats with cells that produce high levels of IFNγ caused severe 
cachexia and also led to increased levels of ubiquitin (69). 
A proteolysis-inducing factor (PIF) has been described initially in animal models as a 
glycoprotein secreted by tumors (70) that increases protein degradation by increasing the 
activity of the ubiquitin-proteasome pathway (71). The true existence of a human PIF 
homologue has been debated. An independent group was unable to confirm its presence in 
cancer cell lines (72) and  this was rebutted with possible methodological issues as the 
reason for the inability to detect PIF in such cases (73). Recently, a third independent 
detected PIF in a sample of non-small cell lung cancer patients and reported its association 
with survival and weight loss (74). 
 
Trophic influence on skeletal muscle in cancer cachexia 
Muscle hypoanabolism is tightly related to insulin resistance, hypogonadism, and 
physical inactivity, issues frequently present in patients with cancer. In healthy individuals, 
insulin exerts anabolic effects over the muscles. Muscle resistance to the anabolic effects of 
insulin has been shown in a tumor-bearing rat model (75, 76). Resistance to the anabolic 
effects of insulin has already been described in elderly, obese and diabetic adults. There is 
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no definitive proof that cancer causes insulin resistance, however, since these conditions 
frequently co-occur in patients with cancer, it is likely that insulin resistance plays a role in 
the genesis of muscle wasting in cancer patients (77). 
Physical activity is an important trophic factor for skeletal muscle, while inactivity 
leads to muscle wasting. It has been shown in healthy elderly individuals that even a bed rest 
as short as 10 days lead to a significantly increased tendency to muscle loss (78, 79). It is 
likely that physical inactivity also plays a role in cancer cachexia, considering that cancer 
patients tend to spend a significant amount of time in the hospital in the last year of life (80). 
Hypogonadism has been reported as frequent in a sample of 47 male patients with 
advanced cancer, with a prevalence of 81%. It impacts mood, fatigue, and more importantly, 
cachexia/anorexia symptoms (81). At the level of the hypothalamus, hypogonadism might 
be mediated by cytokines and drugs which lead to decreased gonadotrophin-releasing 
hormone production. At the testicular level, testosterone reduction may be caused, in cancer 
patients, by direct effect of chemotherapeutic drugs or by IL6. Opioid analgesics, megestrol 
acetate, and corticosteroids are frequently used in patients with advanced cancer and are 
concurrent causes of hypogonadism (77). Hypogonadism reduces an important anabolic 
stimulus to skeletal muscle, leading to muscle depletion. 
 
Inflammation 
From the mechanisms described above, it is clear that inflammation plays a major role 
in the genesis of primary cancer cachexia. Increase in inflammatory mediators can be 
brought about by several factors in the patient with cancer: the tumor cells can generate 
some amount of proinflammatory cytokines; the patient’s immune reaction (recruitment of 
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immune cells to the tumor bed) brings up an increase in cytokine production; alterations in 
the gastrointestinal tract; production of cytokines in the muscles and adipose tissue 
themselves; and arise from secondary conditions such as infections (82). 
The tumor environment is rich in inflammatory cytokines, some generated by the tumor 
itself, and most generated by the host reaction to the tumor presence by recruitment of 
macrophages to the tumor site. The presence of such cells in the tumor bed create a pool of 
cytokines, chemokines, angiogenesis-promoting factors, reactive oxygen species (ROS), 
matrix metalloproteinases, and prostanoids (83, 84) which only represent part of the greater 
inflammatory process in the whole tumor-bearing host. 
In the course of cancer treatment, and as a result of several chemotherapy regimens (85, 
86), alterations in the integrity of the gastrointestinal tract lead to impairment of its barrier 
function, allowing for the passage of bacterial endotoxins into the blood (87). The 
endotoxins transported to the blood are a very potent stimulus for cytokine liberation by 
mononuclear cells, and are considered to be a probable trigger for systemic inflammatory 
response which drives cachexia (77). 
Inflammatory drive in patients with cancer can be triggered by the presence of 
concurrent chronic diseases. Patients with cancer usually are towards the 5
th
 decade of life or 
later, therefore at greater risk for chronic diseases such as cardiac failure, pulmonary 
diseases, arthritis, and renal disease. In addition, patients with cancer are at greater risk for 
infections. The presence of such comorbidities significantly increases the inflammatory 
burden in cancer patients, contributing to the genesis of cancer cachexia (77). 
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CHAPTER 2 – Curcumin 
 
Origins and biochemistry 
Curcumin is the phytochemical component responsible for the characteristic yellow-
gold color of turmeric (also known as Indian Curry) a spice used mostly in Asia. Found in 
the root of the Curcuma longa plant, a member of the ginger family (Zingiberaceae), 
turmeric is used not only as a condiment but also to treat several medical issues since around 
1900 BC both in the Ayurvedic and Traditional Chinese medicines (88). 
First isolated in 1815, curcumin had its structure determined as diferuloylmethane [1,7-
bis(4-hydroxy-3methoxyphenyl)-1,6-heptadiene-3,5-dione] in 1910. It is now known that in 
addition to curcumin, two other curcumin analogues are found in turmeric: 
demethoxycurcumin and bisdemethoxycurcumin. Even though there is evidence pointing 
towards curcumin as the most effective among the three (89, 90), there is also some 
evidence that bisdemethoxycurcumin might be most effective (91) and even that the 
combination of the three analogues is what actually exerts the best action (92-94). Most 
commercially available preparations have around three-fourths diferuloylmethane, one-fifth 
demethoxycurcumin, and 5% bisdemethoxycurcumin. 
Following oral administration, curcumin is metabolized into curcumin glucuronide and 
curcumin sulfonate, while when administered intravenously, it is converted into 
tetrahydrocurcumin, hexahydrocurcumin, and hexahydrocurcuminol. Curcumin is highly 
hydrophobic and has very poor bioavailability because of its very low serum and tissue 
levels, rapid metabolism, and rapid elimination (95). Efforts are underway to overcome this 
issue, such as the development of a liposomal curcumin (96), the use of nanoparticles for 
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curcumin delivery (97), the concomitant administration of adjuvants such as piperine (98), 
insert structural modifications into the molecule (99), and the use of bioconjugates (100).  
 
Actions and molecular targets 
Several actions have been ascribed for curcumin: anti-inflammatory, antioxidant, 
antiprotozoal, nematocidal, antibacterial, and anticancer, among others (101). Probably the 
most widely studied action of this compound is the anti-inflammatory, which makes it an 
interesting drug to be studied for the treatment of cancer cachexia. 
Curcumin interacts with multiple molecular targets of interest for cancer cachexia 
treatment. With regards to transcription factors, it has been shown that curcumin is capable 
of inhibiting the activation of nuclear factor κB (NF-κB), peroxisome proliferator-activated 
receptor γ (PPARγ), signal transducer and activator of transcription proteins (STAT), and β 
catenin. Additionally, it also acts inhibiting the mitogen-activated protein kinase (MAPK) 
pathway, paramount for inflammatory cascades (102). 
In the oncology setting, curcumin has been widely studied for both treatment and 
prevention of several types of cancers, because of is proven ability to inhibit cell 
proliferation and invasion, to block angiogenesis, and to impair the progression of metastasis 
(103). Of interest to this work, our group conducted a Phase II clinical trial in which a total 
of 48 advanced pancreatic cancer patients received 8g of oral curcumin daily for the 
investigation of its safety and antitumor activity. Objective responses were seen in two 
patients: one had a short-lived marked tumor reduction  of 73% followed by increases in 
tumor size in subsequent re-evaluations and one had prolonged stable disease (greater than 8 
months at publication which happened when accrual reached 25 patients) (104). Of note, 
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curcumin was overwhelmingly very well tolerated, and no toxicities were observed by the 
time of publication. In the treated patients, NF-κB, cyclooxygenase-2, and phosphorylated 
signal transducer and activator of transcription 3 (STAT-3), which were higher than healthy 
individuals at baseline, were reduced after treatment with curcumin, showing a potential 
effect of the drug on these targets (104). 
 
Curcumin and cachexia 
The effects of curcumin in cachexia (specifically in muscle loss) have been studied by 
several groups in animal models, yielding conflicting results. Busquets et al. studied the 
antitumor and anticachectic effects of curcumin in a Wistar rat model innoculated with the 
cachexia inducing Yoshida ascites hepatoma cells. Even though the investigators were able 
to show a significant tumor reduction effect, no anticachectic effect was identified (105). 
Another group, studying the effects of resveratrol and curcumin single-agent in a mice 
model with implanted MAC16 colon tumor cells was able to observe attenuation in total 
protein degradation with both drugs. In this model, however, curcumin was not able to 
prevent weight loss and muscle protein degradation, and this was ascribed to its low 
bioavailability (106). A third group studied the effects of curcumin on proteolysis and 
muscle wasting both in vitro and in vivo (in a mice model with MAC16 colon tumor), and 
was able to show a clear effect of weight loss reversal in mice treated with curcumin (107). 
Other groups were able to show anticatabolic effects of curcumin in animal models of 
sepsis, injury, and endotoxemia (108-110). To date, the effects of curcumin in cancer 
cachexia were not studied in humans. 
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CHAPTER 3 – RATIONALE, HYPOTHESIS, AND AIMS 
 
Rationale 
Cachexia is related to shorter survival and worse quality of life in patients with 
advanced cancer. It is a multifactorial syndrome, in which loss of body weight (both fat and 
muscle losses) is always present. Even though several mechanisms have been implicated in 
its genesis, with inflammation playing a crucial role, there are very few evidence-based 
strategies to date to face this problem. Curcumin has very potent anti-inflammatory 
properties and therefore its impact on body composition is being studied in the current work. 
 
Hypothesis 
Patients with advanced pancreatic cancer treated with curcumin for two months have 
less fat and muscle loss as compared to matched controls not treated with this compound. 
 
Specific Aims 
1. To determine the evolution of body tissue composition in patients with pancreatic 
cancer treated with curcumin.  
2. To determine whether there is a difference in body tissue composition over time 
between patients with pancreatic cancer treated with curcumin and matched 
untreated patients. 
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CHAPTER 4 – METHODOLOGY 
 
Patient population 
The patient population for this retrospective observational study is composed of two 
groups. The first group (treatment group) was obtained from a sample of patients with 
advanced pancreatic cancer who participated on a clinical trial conducted at the 
Investigational Cancer Therapeutics department at the University of Texas MD Anderson 
Cancer Center between December/2004 and February/2006 (Protocol ID03-0009, Principal 
Investigator Professor Razelle Kurzrock MD). These patients ingested daily eight one-gram 
capsules containing 900mg of curcumin (90%), 80mg of desmethoxycurcumin (8%), and 
20mg of bisdesmethoxycurcumin (2%) supplied by Sabinsa Corporation. The concentrations 
of each of the curcuminoids contained in the capsules were confirmed by mass spectrometry 
before the beginning of the trial (104). Forty-nine patients were treated on the clinical trial 
and were considered for inclusion in the current study. The second group (control group) is 
composed of patients with advanced pancreatic cancer treated at The University of Texas 
MD Anderson Cancer Center between December/2004 and February/2006 who did not 
receive curcumin.  
The eligibility criteria for this study were expanded from the original clinical trial 
(inclusion a-g and exclusion)(111) and were as follows: 
 
Inclusion criteria 
a. “The patient had pathologically confirmed adenocarcinoma of the pancreas 
that was not amenable to curative surgical resection (includes locally 
advanced, metastatic, or recurrent disease). 
 17 
 
b. The patient had a Karnofsky Performance Status of  ≥ 60 at study entry. 
c. The patient had ≥ 18 years of age. 
d. The patient had adequate hematologic function as defined by an absolute 
neutrophil count ≥ 1,500/mm2, platelet count ≥ 100,000/mm3. 
e. The patient had adequate hepatic function as defined by a total bilirubin ≤ 2 
X ULN, alkaline phosphatase, ALT and/or AST ≤ 5 X ULN, and creatinine ≤ 
2.0 mg/dL. 
f. The patient had measurable disease. 
g. The patient agreed to use effective contraception if procreative potential 
exists (for enrollment on the original clinical trial)” (111) 
h. The patient in the treatment group had one abdominal CT image including the L3 
vertebra level 28±7 days before the first day of treatment (baseline image) and one 
similar image within 60±20 days after the first day of treatment (follow up image). 
i. The patient in the control group had two abdominal CT images including the L3 
vertebra level separated by a range of 60±20 days. The number of days between the 
first image and the diagnosis of advanced pancreatic cancer must be within 30 days 
of the same difference for the matched treatment group patient. 
 
Exclusion criteria 
a. “The patient had a history of treated or active brain metastases, 
carcinomatous meningitis, an uncontrolled seizure disorder, or active 
neurological disease. 
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b. The patient had received prior radiation. Patients with measurable disease 
outside the radiation port or documented disease progression of previously 
irradiated measurable disease were eligible. Patient must be ≥ 4 weeks post-
therapy and have recovered from all toxicities. 
c. The patient had an unstable medical condition according to the investigator, 
including uncontrolled diabetes mellitus or hypertension; active infections 
requiring systemic antibiotics, antivirals, or antifungals, unstable CHF, 
uncontrolled arrhythmias, or unstable coagulation disorders. 
d. The patient was pregnant or breast feeding. 
e. The patient had received an investigational agent(s) within four weeks of 
study entry.” (111) 
 
Control matching procedure 
Subjects in the control group were matched to those in the treatment group on a 1:2 
matching ratio according to gender, age (within a range of ± 5 years), body mass index (± 5 
kg/m
2
), Karnofsky performance status (± 20), number of prior therapies (± 2), and time 
between first CT and advanced cancer diagnosis (± 3 months). Charts of all potential 
controls were reviewed and data collected regarding the matching variables. All charts 
received then a computer-generated random study accession number and the list of charts 
was ascendantly sorted. The list was then searched from lowest to highest accession number 
to find the first two adequate controls for each patient in the treatment group. This was done 
by sequentially identifying matching gender, age, time from advanced cancer to baseline 
image, body mass index, number of prior therapies, and performance status. On a first 
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round, all controls who matched all variables were identified. Then, for patients with no 
perfect matches available, variables were excluded from the matching procedure one by one 
in reverse order to allow an even distribution of mismatches across the matching variables. 
For example: the first variable not to be considered in the second matching round was 
“performance status”. Therefore, remaining potential controls are searched for matches with 
regards to the other five variables and the selected control is the one with the lowest 
accession number that has performance status closest to the matching range. Once one 
treated patient is matched to a control in this round, the match search for another patient 
starts by excluding the variable “number of prior therapies” from the procedure and 
matching all other five variables. Whenever another treated patient is matched to the control 
with lowest accession number and closest “number of prior therapies” in this fashion, the 
match search for a third patient starts, now excluding the variable “body mass index” and so 
on.  
 
Data collection 
Basic demographic data, date of advanced pancreatic cancer diagnosis (defined as 
locally advanced, recurrent, or metastatic), laboratory results, presence of ascitis and/or 
edema, height, and weights were collected by chart review. Anticancer treatment history, 
use of corticosteroids, progestins, androgens, and cannabinoids were also obtained from the 
electronic charts. 
Body mass indices (BMI) were calculated by dividing the weight (in kilograms) by the 
height (in meters) squared (112). Patients were considered to be overweight or obese if they 
had BMI ≥ 25.0 kg/m2 (113).  
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Eligible abdominal CT images were identified by chart review and downloaded from 
the institutional PACS (Picture Archiving and Communication System) network. In addition 
to the baseline and follow up images described under “eligibility criteria”, one additional 
image, 60±20 days before the baseline image, was downloaded for patients in whom it was 
available (pre-baseline image). 
 
Body composition determination by CT image analyses 
The gold standard for determination of body composition is the dual X-Ray 
absortiometry (DEXA), in which the different compartments of the body are determined by 
the detection of the amount of radiation that is able to pass through different tissues (114). 
However, it is not regularly clinically used in the population of patients with cancer. Indeed, 
none of the patients treated with curcumin in the previous study had performed this 
evaluation and therefore it was impossible to use this method for the purpose of this work. 
Conversely, CT images are frequently obtained in the course of standard cancer care, and 
provide direct view of the body fat and muscle compartments. In fact, it has been shown that 
CT images are appropriate for body composition analyses in healthy populations (115, 116). 
Mourtzakis et al have shown in cancer patients that quantification of the fat and muscle 
contents found on a single abdominal CT slice at the level of the third lumbar vertebra (L3) 
provide very adequate correlation with DEXA results (r = 0.82 and r = 0.89, for fat and fat-
free masses, respectively, with p<0.001 for both correlations) (117). 
Procedure 
The evaluation of body composition by CT analysis is based on the fact that different 
body tissues absorb different amounts of radiation, allowing their identification and 
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quantification (118). The amount of radiation absorbed by a tissue is measured in  
Hounsfield units (HU), in which the amount of X-ray energy absorbed by water is defined as 
0 HU and then the percent absorption coefficient for bone is equivalent to 100 HU, and for 
air is equivalent to -100 HU (119). It is known that skeletal muscle is characterized by a 
range of -29 to 150 HU, subcutaneous and intramuscular adipose tissues by a range of -190 
to -30 HU (120), and visceral adipose tissue by a range of -50 to -150 HU (121). 
 
 
FIGURE 2 – CT image body composition determination procedure. 
 
CT images are generated in a data format in which it is possible to determine the 
amount of Hounsfield units per pixel (118). For this study, this determination was performed 
by using Tomovision SliceOMatic computer software (Tomovision, Montreal, QC, Canada). 
Abdominal CT images at L3 level were identified for all study subjects by chart review and 
downloaded. Their identifiers were removed and the images were randomized for blinded 
analysis. Each raw image was then loaded with the SliceOMatic software and the different 
compartments (skeletal muscle and visceral, subcutaneous, and intramuscular adipose) were 
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manually identified and marked according to their anatomical distribution and following the 
described X-ray absorption coefficients (Figure 2). After completion of the identification of 
the specified areas, the software calculates the area of each compartment, by multiplying the 
number of pixels marked for each of them by the known area of each pixel.  
A height-normalized muscle index is calculated by dividing the area of skeletal muscle 
at L3 in centimeters squared by the height (in meters) squared (122). Patients were classified 
as having sarcopenia (reduced muscularity) according to muscle index cutoffs previously 
described of 52.4 cm
2
/m
2
 for men and 38.5 cm
2
/m
2
 for women (123). 
The areas of skeletal muscle and fat were used to estimate the total body fat and lean 
masses, according to the following formulae described by Mourtzakis et al (115): 
                                            and              
                           ), which have good correlation with DEXA measurements 
(r=0.94, p<0.0001 and r=0.88, p<0.0001, respectively) (117). 
 
Statistical analyses 
Descriptive statistics were used to summarize the data. Continuous variables were 
tested for normality using the Kolmogorov-Smirnov test. Means and standard errors of the 
means were used for summarizing continuous variables with normal distribution, while 
medians and ranges were used for summarizing continuous variables which did not follow a 
normal distribution pattern. For consistency when presenting comparisons between variables 
in which normality could not be assumed for all groups, medians and ranges were used to 
summarize the data. Categorical variables were summarized by frequency. Differences in 
categorical variables were tested for statistical significance by using the chi-squared or 
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Fisher exact tests, where appropriate. Differences in paired continuous variables were tested 
by paired t-tests when the underlying distribution was normal and by the Wilcoxon rank-
sum test when not normally distributed. Statistical significance for differences between 
independent continuous variables was evaluated by t-tests and Mann-Whitney tests 
depending if normality was respectively assumed or not. Correlations were evaluated by 
Pearson or Spearman coefficients, whenever appropriate also according with normality. 
Survival analyses were conducted using Kaplan Meier plots with log-rank analyses. Patients 
for whom date of death was not found were censored at the time of last follow up. 
Differences were deemed to be statistically significant when the p values were less than or 
equal to 0.05. All analyses were performed using SPSS v. 16 (SPSS Inc, Chicago, IL). 
Selected graphs were composed using GraphPad Prism v. 5.04 (GraphPad Software, Inc., La 
Jolla, CA). 
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CHAPTER 5 – RESULTS 
  
Study sample 
Forty-nine patients were treated on protocol and were therefore considered for the 
treatment group. Baseline images were available for all patients. However, 20/49 patients 
(41%) were excluded because they did not have a follow up image. The reasons for lack of 
images were: (a) patients died before restaging was performed (n=6/20, 30%), (b) patients 
taken off study because of disease progression or clinical worsening (n=7/20, 35%), (c) 
patients transferred to other services or lost to follow up (n=5/20, 25%), and (d) patients 
were prematurely taken off study because of drug intolerance (n=2/20, 10%). Three 
additional patients were excluded from the study sample because they had no suitable 
images, and for four patients it was not possible to identify suitable controls. Reasons for 
exclusion are summarized in Figure 3. As a result, 22 patients had two images meeting the 
inclusion criteria and available controls, being included in the study group.  
 
 
FIGURE 3 – Study population flowchart (PD=Progressive disease, SE=Side effects). 
 
 
49 patients
Received curcumin on the previous protocol
20 (41%) no follow up image
6 (30%) died
7 (35%) off study (PD)
2 (10%) off study (SE)
5 (25%) transferred / lost to f/u
22 patients
“Treatment group”
3 (6%) innappropriate images
4 (8%) no suitable control identified
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The treatment group was composed by 10 women (45.5%) and 12 men (54.5%), with 
median age 65.5 years (range 40-77). The median number of prior systemic therapies for 
this group was 2 (range 0-6), and the median Karnofsky performance status was 80% (range 
60%-100%).   
Potential patients for the control group were pooled from all patients with pancreatic 
cancer registered at the institution (excluded the 49 patients treated on the curcumin clinical 
trial) who were seen between January/2005 and February/2006 (n=948). Of those, 399 
(42%) patients were excluded because they have had only one abdominal CT performed 
within the timeframe, being ineligible for the study. Of the remaining 549 patients, 309 
(56%) had at least two images separated by 60±20 days, being selected to compose the pool 
of patients potentially eligible for the control group. The two best matches for each patient 
were selected to compose the control group, and the overall matched patient characteristics 
are shown in Table 1. Median (IQR) time between baseline and follow up images was 63 
(52-67.5) and 66 (59.75-75.25) days for patients in the treatment and control groups, 
respectively (p=0.04). 
 
Treatment Control 
p value 
  (N=22) (N=44) 
Female Gender (n, %) 10 (45.5%) 20 (54.5%) 1.000 
Age (years) (mean, SEM) 63.8 (2.2) 63.2 (1.3) 0.823 
Body Mass Index (mean, SEM) 23.8 (0.6) 24.1 (0.4) 0.707 
Number of prior therapies 
(median, IQR) 
2 (1-3) 2 (1-2) 0.237 
Time between advanced cancer and 
baseline image (months) 
(median, IQR) 
7 (2-13.5) 6 (3-13.75) 0.749 
 
TABLE 1 – Results of the matching process (SEM = standard error of the mean, IQR = 
interquartile range). 
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Body weight 
Body weight and body mass index (BMI) data for patients without ascitis and/or edema 
is summarized in Table 2 [ascitis and/or edema were present in 4/22 (18%) patients in the 
treatment group and in 10/44 (23%) patients in the control group (p=0.759)]. The majority 
of patients lost weight between baseline and follow up in both study groups, with a greater 
frequency of weight losers in the treatment group [15/18 (83%) and 19/34 (56%) in the 
treatment and control groups, respectively, p=0.07]. The absolute average weight loss in this 
timeframe was somewhat greater in the treatment group [2.4 kg (SEM 0.8)] in comparison 
with the control group [1.1 kg (SEM 0.6)], not reaching statistical significance (p=0.174). 
The average percent weight loss was of 3.3% of the baseline weight for the treatment group 
and 1.3% of the baseline weight for the control group, also not reaching statistical 
significance (p=0.130) (Figure 4). Weight change was not different according to gender in 
any of the groups. 
 
  
Weight (kg) BMI (kg/m2) 
  
n (SEM) P n (SEM) p 
Treatment 
Baseline 69.4 (2.4) 
0.007 
23.9 (0.5) 
0.006 
Follow up 67.0 (2.2) 23.1 (0.5) 
Variation -2.4 (0.8) -.- -0.8 (0.3) -.- 
        
Control 
Baseline 69.0 (2.2) 
0.05 
24.0 (0.5) 
0.05 
Follow up 67.9 (2.0) 23.6 (0.4) 
Variation -1.1 (0.6) 0.175* -0.4 (0.2) 0.160* 
 
* p values for the comparison between the variations in the Treatment and Control groups. 
 
TABLE 2 – Weight and BMI values for patients in both study groups at the 2 time points. 
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FIGURE 4 – Percent weight change in the study groups. (Whiskers represent the SEM) 
 
According to usual BMI cutoffs, 6/18 (33%) treated patients and 12/34 (35%) controls 
were considered to be overweight or obese at baseline (p=1.000) and 4/18 (22%) and 11/34 
(32%) were classified as overweight or obese at follow up (p=0.532). 
 
Body composition  
All body composition parameters decreased in both groups between baseline and follow 
up. The evolution of body composition variables is summarized in Table 3. No significant 
differences were found with regards to such variables between patients in the treatment and 
control groups at baseline. At follow up, the treatment group showed a trend towards lower 
subcutaneous fat area at L3, total adipose area at L3 and total estimated body fat. 
 
%
 o
f 
b
a
s
e
li
n
e
 w
e
ig
h
t
Baseline Follow up
0
70
75
80
85
90
95
100
Treatment
Control
p=0.130
100%
98.7%
96.7%
 28 
 
 
Baseline Follow up 
 
Treatment Controls 
p 
Treatment Controls 
p 
 
N=22 N=44 N=22 N=44 
  Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Skeletal muscle 
area at L3 (cm
2
) 
119.7 (104-145.7) 125.1 (108-146.7) 0.661 112.5** (95.6-137.5) 122.6 (102-149) 0.202 
Muscle index 
(cm
2
/m
2
) 
42.3 (37-46.7) 42.3 (37.6-47.4) 0.747 40.2** (35.6-45.4) 41.6 (37.5-46.8) 0.115 
Intramuscular 
adipose area at 
L3 (cm
2
) 
7.5 (3.4-12) 7.9 (5.4-11) 0.833 7.7 (2.5-10.5) 7.0 (4.9-13) 0.430 
Visceral adipose 
area at L3 (cm
2
) 
57.3 (36.4-133.2) 73.4 (44.7-116.6) 0.668 42.3* (26.2-101) 68.5* (35.7-104) 0.286 
Subcutaneous 
adipose area at 
L3 (cm
2
) 
95 (65.7-191.9) 120 (101.6-172.7) 0.331 72.7** (59.9-160.5) 116.7* (84.6-149.2) 0.054 
Total adipose 
area at L3 (cm
2
) 
208.9 (119-317.5) 228.4 (147.3-294.8) 0.732 137.8** (85.8-266.8) 217.8* (154.2-282.9) 0.07 
Estimated total 
lean body mass 
(kg) 
42 (37.3-49.8) 43.6 (38.5-50.1) 0.661 39.8** (34.7-47.3) 42.8 (36.7-50.8) 0.202 
Estimated total 
fat body mass 
(kg) 
20 (16.2-24.5) 20.8 (18.5-23.6) 0.732 17** (14.8-22.4) 20.4* (17.7-23.1) 0.07 
 
 
* statistically significant differences between baseline and follow up time points within study groups. (* p < 0.05; ** p<0.001) 
 
 
TABLE 3 –Body composition variables in both groups at baseline and follow up. (IQR = interquartile range).
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Percent variation in body composition variables according to study groups are shown in 
Figure 5. Patients in the treatment group showed greater percent reduction in all parameters 
when compared to those in the control group. Significantly different reductions were 
observed for skeletal muscle area at L3, intramuscular adipose area at L3, total adipose area 
at L3, estimated total adipose body mass, and estimated total lean body mass. The median 
percent change in estimated total lean body mass and total adipose body mass was 
significantly greater for treated [-4.8% (IQR -9.1 to -0.1) and -6.8% (IQR -15 to -0.6), 
respectively] than for untreated patients [-0.05% (IQR -4.2 to 2.6) and -4.0% (IQR -7.6 to 
1.3), respectively] (p<0.001 and p=0.04 for lean and fat body mass changes, respectively). 
The difference in percent changes for estimated total lean and adipose body masses was not 
statistically different among curcumin treated patients, but was significantly different among 
the controls, with the fat loss being greater (p=0.03). 
Sarcopenia was present in 15/22 (68%) treated patients and 27/44 (61%) controls at 
baseline (p=0.787). At follow up, sarcopenia was present in 18/22 (82%) treated patients and 
29/44 (66%) controls (p=0.252). Sarcopenia combined with overweight or obesity (BMI ≥ 
25kg/m
2
) occurred in 3/18 (17%) and 5/34 (15%) treated and untreated patients at baseline, 
respectively (p=0.574) and in 3/18 (17%) and 3/34 (9%) treated and untreated patients at 
follow up, respectively (p=0.339). Male patients in the treatment group had a significantly 
greater frequency of sarcopenia as compared to female patients in the same group 
[11/12(92%) versus 4/10(40%) at baseline and 12/12 (100%) versus 6/10 (60%) at follow up 
(p=0.020 and 0.029, respectively)]. In the control group, the frequency of sarcopenia in 
males was also greater, however did not attain statistical significance in any of the 
timepoints. No baseline sarcopenic patients reversed their low muscularity status at follow 
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up. However, five patients developed sarcopenia at follow up (2 women and 1 man in the 
treatment group and 2 women in the control group). 
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FIGURE 5 – Percent change in body composition variables between baseline and follow 
up. (Whiskers represent the SEM) 
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With regards to the use of medications that can impact body composition (especially 
affecting muscularity), 4/22 (18%) of the treated patients used such drugs in the study period 
(progestin in three cases and testosterone in one), while 2/44 (4.5%) controls were receiving 
those medications (one progestin and one testosterone) (p=0.09). No patients were found to 
be under treatment with cannabinoids or corticosteroids in the study period. Among the 
treated patients, no difference was found between subjects who received such drugs and 
those who did not receive them with regards to total lean body mass [-6.4% (SEM 3.5) vs. -
4.8 (SEM 1.4), respectively, p=0.523] and total body fat [-9.9% (SEM 4.2) vs. -8.7 (SEM 
2.3), respectively, p=0.58]. Statistical significance was not tested for the control patients due 
to the small number of subjects who received the drugs.  
A proportion of patients in the control group received oncologic treatment in the study 
period (26/44, 59%). Gemcitabine, cisplatin, and oxaliplatin were the most common 
chemotherapeutics used. The percent change in total lean body mass was not statistically 
different between controls who received and did not receive oncologic treatment [-0.7% 
(SEM 0.8) vs. -0.5% (SEM 1.0), respectively, p=0.828]. Similarly, the percent change in 
total adipose body mass was not significantly different between controls according to 
oncologic treatment during the study period [-4.3% (SEM 1.5) vs. -0.7% (SEM 2.3), 
respectively, p=0.179]. 
The correlations between other potential confounders and variations in body 
composition were also analyzed by determining correlations (Table 4). No statistically 
significant correlations were observed. 
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Treatment group Control group 
 
Total lean 
body mass 
variation 
Total body fat 
mass variation 
Total lean 
body mass 
variation 
Total body fat 
mass variation 
 
R p R p R p R p 
Age 0.27 0.232 -0.41 0.062 -0.29 0.79 -0.14 0.372 
Time between 
advanced cancer to 
baseline 
0.04 0.871 0.19 0.405 -0.05 0.748 0.12 0.423 
Baseline albumin -0.29 0.195 0.2 0.372 0.14 0.539 -0.21 0.353 
Performance 
status 
-0.19 0.398 0.21 0.345 0.13 0.398 -0.19 0.214 
Number of prior 
therapies 
0.21 0.343 0.23 0.306 -0.04 0.79 0.09 0.554 
 
TABLE 4 – Correlations between body composition variation and confounding variables. 
 
Survival analyses 
Overall median survival from baseline (95% CI) was of 189 (142-236) days for the 
patients treated with curcumin and 299 (240-357) days for the patients in the control group 
(log rank p=0.065) (Figure 6). Survival was not significantly different between sarcopenic 
and non-sarcopenic patients overall [254 (216-291) vs. 293 (143-443) days, p=0.588]. 
However, when analyzed separately, the 15 sarcopenic patients in the treatment group 
showed significantly shorter survival [169 (115-223) days] in comparison with the 27 
sarcopenic patients in the control group [299 (229-369) days, p=0.024], whereas no 
difference was found between the survival of the seven non-sarcopenic patients in the 
treatment group [254 (216-291)] and the 17 non-sarcopenic control patients [304 (184-423), 
p=0.910] (Figure 7). 
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FIGURE 6 – Kaplan-Meier plot: survival from baseline of patients in the treatment (n=22) 
and control (n=44) groups.  
 
FIGURE 7 –Kaplan-Meier plots: survival of sarcopenic and non sarcopenic patients. 
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Survival was plotted against changes in body composition between baseline and follow 
up for patients in the treatment and control groups whose death was confimed (22/22 and 
42/44, respectively) (Figures 8 and 9). The correlation between the variation of total lean 
body mass and survival yielded coefficients of 0.283 and -0.035 (p=0.202 and 0.824) for 
cases and controls, respectively, whereas the correlation between survival and variation in 
total fat body mass yielded coefficients of 0.367 and 0.058 (p=0.09 and 0.713) for cases and 
controls, respectively. Even though not statistically significant, shorter survival appeared to 
be correlated with greater reductions in body composition parameters only in the group of 
patients treated with curcumin. 
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FIGURE 8 – Percent change in lean body mass according to survival from baseline. Circles 
represent individual patients, solid line the regression line fitted, and dashed lines the 95%CI 
band.  
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FIGURE 9 – Percent change in adipose body mass according to survival from baseline. 
Circles represent individual patients, solid line the regression line fitted, and dashed lines the 
95%CI band.  
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Exploratory pre-baseline data analyses 
Weight data was available for 10/22 (45%) patients in the treatment group and for 17/20 
(85%) of their controls. Since one of the treated patients had no controls with prebaseline 
weights available, this triad was excluded from comparative prebaseline weight analysis. 
Similarly to what was found between baseline and follow up timepoints, the majority of 
patients also lost weight between pre-baseline and baseline, with 7/9 (78%) and 15/17 (88%) 
patients losing weight in the treatment and control groups, respectively. Figure 10 
summarizes the evolution of the body weight (in percentage of the pre-baseline weight). The 
variation in percentage of the pre-baseline weight between pre-baseline and baseline time 
points was of -2.4% (SEM 1.5) and -1.9% (SEM 1.6) for the treatment and control groups, 
respectively (p=0.848) and between baseline and follow up time points it was of -3.1% 
(SEM 1.5) and -1.5 (SEM 1.1) of the prebaseline weight for the treatment and control 
groups, respectively (p=0.403). 
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FIGURE 10 – Percent weight changes at three time points. (Whiskers represent the SEM) 
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Treatment responders exploratory analyses 
Two patients had significant responses to the previous clinical trial. One of them had 
prolonged stable disease for more than 9 months and the other had a significant though short 
lived decrease in tumor size [decrease of 73% of the baseline tumor size by RECIST 
measurements (124)]. No information was available regarding pre-baseline weights on these 
patients. Data regarding weight and body composition for the baseline and follow up time 
points are summarized in Table 5. Weight loss in both patients was lower than the average 
weight loss for the overall treatment group (3.3%), and the slight increase in total body 
adipose mass was a departure from the average reduction of 8.9% in the treatment group. 
The patient with partial response had a decrease of total lean body mass greater than the 
average decrease of 5.1% in the treatment group, whereas the patient with prolonged stable 
disease had a slight increase in this variable. 
 
 
Partial response patient Stable disease patient 
 
Treated Control A Control B Treated Control A Control B 
% weight change 
from baseline 
-1.4% +1.2% +4.0% -0.6% +3.2% +4.6% 
% lean body mass 
change from 
baseline 
-7.3% +3.7% +5.5% +0.6% +5.7% +5.5% 
% adipose body 
mass from baseline 
+0.8% -3.8% +6.0% +0.4% +1.1% +6.0% 
 
TABLE 5 – Body composition changes in the responder patients and their controls. 
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CHAPTER 6 – DISCUSSION 
 
Curcumin did not seem to reverse nor attenuate body mass losses 
The hypothesis for this study was that patients with advanced pancreatic cancer treated 
with curcumin for two months have less fat and muscle loss as compared to matched 
controls not treated with this compound. In order to evaluate this, the evolution of weight 
and body composition was observed in a group of 22 patients who received the drug and 44 
controls who did not receive it, matched according to gender, age, time from advanced 
cancer diagnosis, body mass index, and number of prior therapies (refer to Table 1 for a 
summary of the matching variables).  
This study showed that the sample of patients treated with curcumin for two months 
lost weight due to both fat and muscle losses, therefore the drug seem to not play a role in 
reversing body mass loss in those patients. The weight loss is in line with the previously 
described evolution of body composition in populations of patients with pancreatic cancer. 
Wigmore et al. showed in a prospective observational study of 20 advanced pancreatic 
cancer patients that absolute fat and muscle losses measured by bioelectrical impedance are 
significantly different between diagnosis and death (125). Using the same retrospective CT 
analysis technique as this study, Tan et al. also described that the majority of patients with 
advanced pancreatic cancer lost body mass from both fat and muscle compartments as the 
disease evolved (126).  
Attenuation of weight loss by curcumin in the setting of pancreatic cancer was 
previously described in animal models only. One study in an animal model of cachexia 
(MAC16 colon tumor-bearing mice) showed that the administration of a 100mg/kg dose of a 
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curcumin complex (curcumin c3, composed of 72% curcumin, 22% desmethoxycurcumin, 
and 4% bisdesmethoxycurcumin) was able to attenuate weight loss in the animals (107). In 
addition to the fact that animal models frequently do not translate well to human clinical 
practice (127), it is of interest to note that the analogue composition of the drug used in the 
current study was somewhat different than the used in this animal study (87.2% curcumin, 
10% desmethoxycurcumin, and 2.3% bisdesmethoxycurcumin) (104), which might also 
contribute for the different findings. Indeed, it appears that each curcumin analogue might 
have different activities and potencies, but this is still to be completely determined (128). 
Therefore, further research is needed to investigate if distinct curcumin analogues or 
combinations can differentially affect body weight. Two other groups, one studying the 
effects of curcumin on rats bearing the Yoshida AH-130 ascitis hepatoma cells (which is 
known to cause cachexia) (105), and another in mice bearing MAC16 tumor cells (106) did 
not show the weight loss attenuation found in the previously described animal study (107). 
Interestingly, the latter showed an attenuation of the PIF-induced proteasome expression in 
murine myotubes treated with curcumin in vitro (106). 
In the present study, both treatment and control groups showed statistically significant 
absolute and percent weight losses, with greater losses in the curcumin treated group. The 
difference in absolute and percent weight loss was not statistically significant between the 
two groups after approximately 2 months. Therefore, our findings do not support the 
hypothesis of this study. Of note, the different compartments of body composition, while 
consistently decreased, did so in a different fashion between groups. 
At baseline, the area of all body compartments measured at L3 (subcutaneous, 
intramuscular and visceral fat and skeletal muscle) were similar between groups, as 
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therefore were the estimated total lean and adipose body masses (Table 3). At follow up, 
significant differences were found when comparing the percent reduction in areas of skeletal 
muscle and subcutaneous fat between treated and untreated patients. As expected from these 
results, both estimated total lean body mass and total adipose body mass showed 
significantly greater reductions in the treatment group (Table 3 and Figure 5). In addition, 
patients in the control group lost significantly more adipose tissue than muscle whereas 
treated patients lost comparable percentages of muscle and fat. 
Efforts are being made towards the creation of a classification of cancer cachexia. 
Recently, a preliminary classification of cancer cachexia in three severity degrees 
(precachexia, cachexia, and refractory cachexia) was proposed (10). Patients with refractory 
cachexia, as the name implies, do not respond to therapies aimed at reversing the process 
and invariably undergo a progressive worsening of body composition variables. It might be 
that the patients in this study were towards this end of the cachexia spectrum, therefore 
being not amenable to reversal of the cachexia process. It is not possible to definitively 
identify if the patients in the current study had refractory cachexia, due both to its 
retrospective nature and to the lack of a clear and validated definition of the cachexia 
severity degrees. 
Mounting evidence exists on the potential effects of curcumin in the adipose tissue and 
more so in modulation of signal transduction pathways that are paramount for the genesis of 
obesity and several of its complications (129). The present study showed that patients with 
advanced pancreatic cancer treated with curcumin had significantly greater losses of fat as 
compared to matched untreated controls (Figure 5). This might indicate a direct effect of 
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curcumin on adiposity which is interesting to be explored in anti-obesity research. Further 
research is needed in larger samples of non-cancer patients and healthy individuals. 
Sarcopenia (decreased muscle mass) was present at baseline in 68% of the patients who 
received curcumin and 61% of the controls, and these prevalences increased at follow up in 
both groups, to 82% and 66% for treated and untreated patients, respectively. These figures 
are greater than the 51% prevalence that we have shown for a sample of 104 patients with 
advanced cancer at our Phase I program (130). This is probably explained by the 
heterogeneous population in the previous study. In the setting of pancreatic cancer, the Tan 
et al. group reported in a set of 44 patients a proportion of 46% sarcopenic patients at 
baseline and of 61% around 135 days later (126). One might interpret that difference as 
caused by a selection of patients in a more advanced stage of disease in our study. 
Interestingly, however, is that the median overall survival after the baseline image in Tan’s 
study is the same as for the patients treated with curcumin in our study (189 days), and 
shorter than the median survival for patients in the control group (299 days). Therefore, it is 
likely that other factors are in play and affecting the genesis of sarcopenia or survival in our 
patients.  
 
Curcumin and survival 
In the current study, patients treated with curcumin had median survival from baseline 
189 days (95%CI 142-246), 110 days shorter than untreated patients (p=0.065). There are 
very few published clinical studies of curcumin in humans, and survival data is scarce. 
Epelbaum et al. studied the effects of curcumin combined with gemcitabine for the treatment 
of advanced pancreatic cancer in 17 patients and reported a comparable median overall 
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survival of 5 months, ranging from 1 to 24 months in the 11 patients who were considered 
evaluable (131). 
In a retrospective analysis of 83 consecutive pancreatic cancer patients referred to our 
Phase I program, it has been shown that they had a median overall survival from referral of 
5 months (95%CI 3.3-6.2 months) (132). This is shorter than the results reported here for 
both study groups from the baseline image [6.3 months (95%CI 4.7-7.9 months) for patients 
treated with curcumin and 10 months (95%CI 8-12 months) for the controls]. For the 
patients in the treatment group, the dates of referral to the Phase I program and baseline 
image are very similar so it is fair to state that patients who received curcumin had an 
overall survival around 1 month longer than the average of referred patients with the same 
diagnosis. Of note, patients in the control group had longer overall survival (5 months) than 
what was reported for patients with the same diagnosis seen at our Phase I program. This is 
of interest because might point out to an unforeseeable selection bias, caused by a systematic 
difference between patients referred to phase I and those who were not. It might be that, 
regardless of the matching efforts, patients in the control group had better health conditions 
at the inception point (time of first image), not being perceived by their physicians as 
candidates to the curcumin clinical trial and therefore not referred. This might be 
contributing to the difference in overall survival between patients in the treatment and 
control groups. In addition, it is important to mention that overall survival is subject to 
interference of all treatments undertaken after the inception point, and that more than 50% of 
the patients in the control group were receiving oncologic treatment at the time of study 
entry and some of the patients in the treatment group received further treatments after being 
taken off the curcumin trial. Therefore, it is not possible to ascribe differences in survival 
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only to the use of curcumin based solely on the data reported here. This is inherent to the 
retrospective design of the current study, despite all matching efforts. 
It was also shown in this work that sarcopenic patients treated with curcumin had a 
median survival significantly shorter (130 days) than sarcopenic patients in the control 
group (Figure 7). Shorter survival in patients with sarcopenia has been previously described 
among overweight pancreatic cancer patients (126) and among obese patients with cancers 
of the gastrointestinal and respiratory tracts (123). Unfortunately, due to the small number of 
patients with combined sarcopenia and overweight/obesity in this study, it was impossible to 
conduct survival analyses to explore the influences of this combination of variables in this 
patient population. It is of interest that sarcopenic patients treated with curcumin had shorter 
survival as compared to untreated patients. Curcumin suffers with low bioavailability issues 
(95), and it might be that the differential distribution in the body tissues in sarcopenic 
patients had driven a particular action of curcumin in those patients. Further research is 
needed to confirm this finding and elucidate the mechanisms by which survival is 
significantly reduced when curcumin is used in patients with sarcopenia. 
An interesting finding relates to Figures 8 e 9, is the apparent correlation between 
percent loss of total lean body mass and total adipose body mass with shorter survival in 
patients treated with curcumin. By observing the graphs, it is possible to note that patients 
who are closer to death and are receiving curcumin present a greater loss of both total lean 
and adipose body masses, while patients in the control group present an almost flat 
regression line, denoting that total lean and adipose body mass losses in these patients 
remain more stable, regardless of the proximity to death. It seems as if patients who receive 
curcumin undergo a metabolic shift towards a more lipolytic weight loss pattern when they 
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are towards the end of their lives. It is not possible to determine causality in this 
retrospective study, but it is plausible to hypothesize that maybe curcumin is having a direct 
effect on the cancer and activating the secretion of LMF (lipid mobilizing factor), for 
example. Further research is needed to prove this new hypothesis. 
 
Potential confounders of body composition changes 
Changes in body composition might be impacted by several factors. Age, for example, 
is well known for being frequently accompanied by fat and muscle loss (133).  Performance 
status might impact body composition to the extent that it impacts physical conditioning 
(134). Considering the very small sample size of the current study, it was not possible to 
generate multivariate models to evaluate the participation of potential confounders of the 
total adipose and lean body mass variation variables. Therefore, the dyadic correlation 
between the potential confounders and each of the body composition percent change 
variables was performed to provide preliminary evidence of their independent association 
with body composition outcomes (Table 4). Interestingly, the correlation coefficients were 
very low and none was statistically significant, pointing towards a small or absent impact of 
those potential confounders, when taken independently, on the results of this study. 
However, further research in larger samples is needed to evaluate the importance of such 
variables in body composition changes in patients with advanced pancreatic cancer. 
Medications such as corticosteroids, androgenic steroids, progestins, and cannabinoids 
more often than not have a role in the therapeutic arsenal of advanced cancer patients. These 
drugs can impact body composition and have to be considered as potential confounders. 
Corticosteroids, for example, when used for long periods of time can cause muscle wasting 
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(135). Androgenic steroids are capable of decreasing weight loss and/or increase muscle 
mass. Nandrolone has been studied in patients with non small cell lung cancer, for example, 
and showed lower frequency and intensity of weight loss in patients who received the drug 
as opposed to patients who did not receive it (136). In patients with COPD treated with 
nandrolone, an increase in fat free muscle mass was shown in comparison with patients 
treated with placebo (137). Progestins are the mainstay treatment for cancer cachexia and 
have a positive orexigenic effect with some gains in weight (138). In the current study, very 
few patients were under treatment with such drugs, and their use was not associated with 
differences in body composition. 
Patients in the control group could be under oncologic treatments during the study 
period, and this is also a potential source of bias since it has been shown in several types of 
cancers that the oncologic treatment itself might have an effect on body composition. In 
patients with breast cancer, for example, an increase in weight mostly due to fat mass has 
been described after oncologic treatment (139). Similar results were described for patients 
receiving chemotherapy for Hodgkins lymphoma (140). In the current study, 59% of the 
control group was under active oncologic treatment with chemotherapeutic and biologic 
anti-cancer agents during the study period. In the control group, no differences were found 
with regards to changes in body composition over time when comparing patients according 
to presence of absence of oncologic treatment.  
 
Exploratory analyses of the best responders 
One important issue regarding the use of curcumin is its very low oral bioavailability in 
the currently available formulations (95). Two patients in particular presented interesting 
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clinical oncologic responses to the drug in the previous protocol: one had a prolonged stable 
disease (more than 9 months) and the other had a 73% tumor reduction that was short lived. 
It is plausible that one of the reasons for these patients to respond to the drug is that their 
organisms are specially equipped to absorb and adequately utilize curcumin (because of 
reasons that are yet to be discovered that might include mutant players in metabolic 
pathways, for example). Therefore, analyses of those particular responders were conducted 
separately, to evaluate if their body composition changes were particularly different than 
that of the majority of the patients on study (Table 5). It was found that both responder 
patients lost weight as their non-responder counterparts but on a smaller percent rate, 
whereas both gained small amounts of fat mass, a completely different result as compared to 
the overall fat loss of almost 9% in the non-responders. Considering this study’s very small 
sample, it is impossible to draw definite conclusions about the body composition behavior of 
those two patients. In addition, it might be the case that the differences in body composition 
changes are reflecting the fact that the patient had an oncologic response and therefore is 
progressing differently than the other patients. Whether curcumin is itself having a different 
action directly on body composition or the changes in body composition are a consequence 
of curcumin action on the cancer is subject for future prospective studies with larger 
samples.  
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CHAPTER 7 – CONCLUSIONS AND FINAL CONSIDERATIONS 
 
This study was not able to confirm the hypothesis that patients with advanced 
pancreatic cancer treated with curcumin for two months have less fat and muscle loss as 
compared to matched untreated controls. Both curcumin-treated and untreated patients lost 
weight due to a combination of fat and muscle depletion. Curcumin treated patients lost 
more weight and had greater losses in all body composition variables. Fat loss was the 
prominent feature in both groups, with different adipose compartments behaving differently: 
the significant fat loss occurred only in the subcutaneous area. Lean body mass loss also 
occurred and was significantly greater in the treated patients.  
Overall, patients on curcumin had a borderline significant shorter survival as compared 
to their untreated controls, and patients on curcumin with sarcopenia had shorter survivals as 
compared to those who did not have sarcopenia. 
Additionally, the current study allowed for the rising of some new research hypothesis 
such as the possible direct effect of curcumin in the tumor activating the secretion of LMF 
and shifting the weight loss from a predominantly proteolytic pattern to a more lipolytic one 
in patients towards the end of life. 
Some limitations have to be cited for this study. The small sample size and its 
retrospective nature impair the ability of drawing definite conclusions. Additionally and also 
related to its retrospective characteristic, the study is subject to selection bias, even though 
several measures were taken to minimize this risk (1:2 matching by several characteristics, 
random selection of controls). However, it is still possible that some remaining systematic 
difference between patients treated with curcumin and controls persisted. For example, all 
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study subjects had the same diagnosis and were treated at M. D. Anderson Cancer Center at 
the same time period. Therefore, it is likely that all of them were treated by a consistent 
“pool” of physicians, who sometimes referred the patients to the curcumin clinical trial and 
sometimes did not. The choice for referral might have been influenced by several factors, 
including the subjective impression of the clinician about the patient’s overall health state. It 
might very well be that patients who were considered in better condition were not referred to 
the curcumin trial because of the impression that those patients were doing well on current 
treatments or could be changed to other therapy lines. This is supported by the finding that 
patients in the control group showed an overall survival about five months longer than what 
was reported for a group of 83 consecutive patients with advanced pancreatic cancer referred 
to our Phase I program. Therefore, it is not impossible that patients in the control group were 
in better overall health state (even though not reflected in the matching variables) at the time 
of baseline imaging when compared to patients in the treatment group. Unfortunately the 
retrospective nature of this study makes it is impossible to precisely quantify the controls’ 
overall health state at baseline beyond what was already performed by the stringent five-
variable matching procedure.
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